Inotiv, Inc.

What they do

Inotiv is a contract research organization (CRO) serving the pharmaceutical and medical device industries, as well as academia and government clients. It provides nonclinical and analytical drug discovery and development services, and sells research-quality animals and diets. Its services focus on bringing new drugs and medical devices through discovery and preclinical phases, and in some cases clinical phases. The company emphasizes laboratory animal care and welfare.

Revenue drivers

• Nonclinical and analytical drug discovery and development services — Inotiv provides CRO services to pharmaceutical and medical device industries, focusing on discovery and preclinical phases. This is a core service offering, though specific revenue contribution is not broken out in the provided excerpts.
• Research-quality animals and diets — The company sells research-quality animals and diets to pharmaceutical, medical device, academia, and government clients. Revenue from this line is not separately quantified in the provided excerpts.

Recent performance

For the quarter ended March 31, 2026, Inotiv reported revenue of $117.7 million, down from $120.9 million in the quarter ended December 31, 2025, and from $138.1 million in the quarter ended September 30, 2025. For the fiscal year ended September 30, 2025, revenue was $513.0 million, with a net loss of $68.6 million and negative operating cash flow of $10.5 million. The company has reported annual net losses since fiscal 2022, including a $337.0 million loss in 2022. As of March 31, 2026, total assets were $702.4 million, total liabilities $625.3 million, and shareholder equity $77.1 million. Cash and equivalents stood at $15.2 million with no long-term debt reported on the balance sheet.

Strategy

Inotiv's strategy, as indicated by forward-looking statements, includes exploring potential recapitalization, reorganization, refinancing, or restructuring transactions, or other strategic alternatives. The company is focused on complying with a Resolution Agreement and Plea Agreement, including a compliance plan and compliance monitor, and managing related cash payments. Management is also executing restructuring and site optimization plans and cost savings initiatives. It aims to manage its substantial outstanding indebtedness, refinance debt, and maintain compliance with financial covenants. The company continues to invest in capacity and services while addressing NHP supply and demand matters.

Risks

• Bankruptcy or insolvency risk — Recent 8-K filings on July 29, 2026, July 16, 2026, and June 3, 2026, include bankruptcy or receivership events, indicating significant financial distress.
• Debt and covenant compliance — Inotiv has substantial outstanding indebtedness and must comply or regain compliance with financial covenants under its Credit Agreement; failure could lead to acceleration or default.
• Regulatory and legal compliance — The company is subject to a Resolution Agreement and Plea Agreement, including a compliance monitor, which could result in ongoing costs and operational restrictions.
• Liquidity and going concern — With $15.2 million in cash as of March 31, 2026, and negative operating cash flow of $10.5 million for fiscal 2025, Inotiv may face challenges funding operations and obligations.

Outlook

Management's forward-looking statements focus on exploring strategic alternatives, including recapitalization, reorganization, refinancing, or restructuring. The company expects to continue managing compliance with its Resolution Agreement and Plea Agreement, and executing restructuring and site optimization plans. It also aims to refinance substantial indebtedness and manage costs. However, actual results may differ materially due to risks including bankruptcy events and liquidity constraints.